Luye Pharma Group (LUP) Stock Statistics & Valuation Metrics
Total Valuation
Luye Pharma Group has a market cap or net worth of EUR 708.25M. The enterprise value is EUR 9.44B.
- Market Cap
- EUR 708.25M
- Enterprise Value
- EUR 9.44B
Share Statistics
Luye Pharma Group has 3,994,515,900 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 3,994,515,900
- Owned by Insiders
- 3.04%
- Owned by Institutions
- 6.20%
Financial Efficiency
Luye Pharma Group’s return on equity (ROE) is 0.04 and return on invested capital (ROIC) is 3.13%.
- Return on Equity (ROE)
- 0.04
- Return on Assets (ROA)
- 0.02
- Return on Invested Capital (ROIC)
- 3.13%
- Return on Capital Employed (ROCE)
- 0.05
- Revenue Per Employee
- 1.20M
- Profits Per Employee
- 117.41K
- Employee Count
- 5,270
- Asset Turnover
- 0.19
- Inventory Turnover
- 2.24
Valuation Ratios
The current PE Ratio of Luye Pharma Group is 7.73. Luye Pharma Group’s PEG ratio is 0.14.
- PE Ratio
- 7.73
- PS Ratio
- 0.87
- PB Ratio
- 0.34
- Price to FCF
- 5.17
- Price to Operating Cash Flow
- 5.51
- PEG Ratio
- 0.14
Income Statement
In the last 12 months, Luye Pharma Group had revenue of 6.31B and earned 618.75M in profits. Earnings per share was 0.16.
- Revenue
- 6.31B
- Gross Profit
- 4.16B
- Operating Income
- 1.24B
- Pretax Income
- 944.64M
- Net Income
- 618.75M
- EBITDA
- 2.06B
- Earnings Per Share (EPS)
- 0.16
Cash Flow
In the last 12 months, operating cash flow was 972.90M and capital expenditures 63.69M, giving a free cash flow of 1.04B billion.
- Operating Cash Flow
- 972.90M
- Free Cash Flow
- 1.04B
- Free Cash Flow per Share
- 0.26
Dividends & Yields
Luye Pharma Group pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 19.33%
- Earnings Yield
- 12.99%
Stock Price Statistics
- Beta
- 0.84
- 52-Week Price Change
- -46.06%
- 50-Day Moving Average
- 0.20
- 200-Day Moving Average
- 0.24
- Relative Strength Index (RSI)
- 33.93
- Average Volume (3m)
- ―
Important Dates
Luye Pharma Group upcoming earnings date is Mar 31, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 30, 2026
- Next Earnings Date
- Mar 31, 2027
- Ex-Dividend Date
- ―
Financial Position
Luye Pharma Group as a current ratio of 1.53, with Debt / Equity ratio of 58.59%
- Current Ratio
- 1.53
- Quick Ratio
- 1.44
- Debt to Market Cap
- 0.98
- Net Debt to EBITDA
- 2.39
- Interest Coverage Ratio
- 1.81
Taxes
In the past 12 months, Luye Pharma Group has paid 238.98M in taxes.
- Income Tax
- 238.98M
- Effective Tax Rate
- 0.25
Enterprise Valuation
Luye Pharma Group EV to EBITDA ratio is 5.05, with an EV/FCF ratio of 9.35.
- EV to Sales
- 1.58
- EV to EBITDA
- 5.05
- EV to Free Cash Flow
- 9.35
- EV to Operating Cash Flow
- 9.96
Balance Sheet
Luye Pharma Group has EUR 10.76B in cash and marketable securities with EUR 12.54B in debt, giving a net cash position of -EUR 1.78B billion.
- Cash & Marketable Securities
- EUR 10.76B
- Total Debt
- EUR 12.54B
- Net Cash
- -EUR 1.78B
- Net Cash Per Share
- -EUR 0.45
- Tangible Book Value Per Share
- EUR 2.47
Margins
Gross margin is 63.75%, with operating margin of 18.49%, and net profit margin of 11.36%.
- Gross Margin
- 63.75%
- Operating Margin
- 18.49%
- Pretax Margin
- 16.35%
- Net Profit Margin
- 11.36%
- EBITDA Margin
- 31.27%
- EBIT Margin
- 17.18%
Analyst Forecast
The average price target for Luye Pharma Group is EUR 0.27, which is 11.43% higher than the current price. The consensus rating is Neutral
- Price Target
- EUR 0.27
- Price Target Upside
- 48.89% Upside
- Analyst Consensus
- Neutral
- Analyst Count
- 1
- Revenue Growth Forecast
- -4.39%
- EPS Growth Forecast
- 59.70%